{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:41:32Z","timestamp":1789062092836,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ardea Biosciences, Inc"},{"DOI":"10.13039\/100010721","name":"Ironwood Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1093\/rheumatology\/key245","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T16:49:47Z","timestamp":1532105387000},"page":"61-69","source":"Crossref","is-referenced-by-count":25,"title":["Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout"],"prefix":"10.1093","volume":"58","author":[{"given":"Robert","family":"Terkeltaub","sequence":"first","affiliation":[{"name":"VA Healthcare System, University of California, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G","family":"Saag","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Goldfarb","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York University School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Clinical Research, Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M","family":"Schechter","sequence":"additional","affiliation":[{"name":"Clinical Research, Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Valiyil","sequence":"additional","affiliation":[{"name":"Clinical Research, Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Jalal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-1542","authenticated-orcid":false,"given":"Michael","family":"Pillinger","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York University School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B","family":"White","sequence":"additional","affiliation":[{"name":"Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"key":"key\n\t\t\t\t2018121406543713600_key245-B1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","article-title":"Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)","volume":"13","author":"Dalbeth","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice. Gout","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B5","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: the LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B8","first-page":"4186","article-title":"Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol","volume":"21","author":"Cutolo","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","article-title":"Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort","volume":"17","author":"Singh","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B10","article-title":"Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout","author":"Huneycutt","year":"2017","journal-title":"J Pharm Pract"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","article-title":"Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney","volume":"18","author":"Miner","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B12","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","article-title":"Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia","volume":"53","author":"Fleischmann","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B13","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B15","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous aout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B17","article-title":"Clinical response of tophus and flares to extended use of lesinurad in combination with a xanthine oxidase inhibitor in patients with gout","volume":"68(Suppl 10)","author":"Bardin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B18","author":"Dalbeth"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B19","article-title":"Examination of serum uric acid (sUA) lowering and safety with extended lesinurad + allopurinol treatment in subjects with gout","volume":"68(Suppl 10)","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9149(03)00659-3","article-title":"Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/ki.2012.208","article-title":"Acute kidney injury and chronic kidney disease: an integrated clinical syndrome","volume":"82","author":"Chawla","year":"2012","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B22","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3899\/jrheum.121061","article-title":"Serum urate and incidence of kidney disease among veterans with gout","volume":"40","author":"Krishnan","year":"2013","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","article-title":"Revisiting comorbidities in gout: a cluster analysis","volume":"74","author":"Richette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/qjmed\/hct083","article-title":"Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality","volume":"106","author":"Stack","year":"2013","journal-title":"QJM"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B25","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2018121406543713600_key245-B26","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","article-title":"Long-term cardiovascular mortality among middle-aged men with gout","volume":"168","author":"Krishnan","year":"2008","journal-title":"Arch Intern Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/1\/61\/27145698\/key245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T23:24:11Z","timestamp":1571613851000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/1\/61\/5074241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,8,14]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key245","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,8,14]]}}}